Clinical Trials Logo

Clinical Outcomes clinical trials

View clinical trials related to Clinical Outcomes.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06219083 Recruiting - Cancer Clinical Trials

Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy

Start date: November 12, 2020
Phase:
Study type: Observational [Patient Registry]

The study investigates the impact of nutritional status on the clinical outcomes of cancer patients in Shaanxi Province undergoing chemoradiotherapy. It focuses on understanding how diet and nutrition affect the effectiveness and side effects of cancer treatments.

NCT ID: NCT05207202 Recruiting - Clinical Outcomes Clinical Trials

Effect of EIT-guided PEEP Titration on the Prognosis of Patients With Moderate to Severe ARDS

Start date: February 20, 2022
Phase: N/A
Study type: Interventional

Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury. Positive end-expiratory pressure (PEEP), as one of main component of MV, has been widely used in the clinical practice. However, the PEEP selection is still a difficult problem for moderate to severe ARDS patients. EIT, an imaging tool evaluating the regional ventilation distribution at the bedside, can achieve the individual PEEP selection for all mechanically ventilated patients. This article compared the effect of PEEP titrated guided by EIT with fraction of inspired oxygen (FiO2)-PEEP table on the clinical outcomes.

NCT ID: NCT04326504 Recruiting - HIV Infections Clinical Trials

Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil

CODE
Start date: February 1, 2021
Phase:
Study type: Observational [Patient Registry]

Access to antiretroviral therapy (ART) in low-income and middle-income countries has been scaled-up effectively over recent years. Recently, the World Health Organization (WHO) guidelines changed to recommend the use of Dolutegravir (DTG) combined with two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir and lamivudine, for first-line ART; however, there is still a need for further data on the outcomes of DTG-based regimens for people with HIV-1. This study aims to describe the outcomes of drug-naïve and experienced patients starting a dolutegravir (DTG)-based regimen in a large cohort of HIV - infected patients in Brazil and compare to outcomes obtained from a retrospective control group of subjects who initiated non-DTG-based ART.